US EditionPfizer Sues to Stop Rival Bid for Drugmaker Metsera by Denmark's Novo Nordisk
Pfizer claims Novo Nordisk's $6 billion bid for Metsera is unlawful and risky, seeking to block the deal amid a competitive takeover fight.
- On Friday after markets closed, New York-based Pfizer sued Metsera Inc. and Denmark-based Novo Nordisk over a bid Novo announced on Thursday.
- In response to competing offers, Pfizer says it is suing Metsera Inc. and Novo Nordisk over a bid Novo announced Thursday, challenging unsolicited competition.
- Metsera has no products on the market but is developing oral and injectable candidates targeting obesity and diabetes, while Novo already markets Wegovy and Ozempic.
- Pfizer is seeking a temporary restraining order in the Delaware Court of Chancery to block Metsera from terminating its merger agreement, arguing Novo's $8.5 billion bid carries significant regulatory risk.
- Novo Nordisk said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera called the offer superior to Pfizer's September bid, while Pfizer said the bid uses `an unprecedented structure designed to deliberately evade antitrust review`.
29 Articles
29 Articles
Pfizer Battles Legal Storm Over Metsera Merger: A High-Stakes Court Drama
Pfizer Battles Legal Storm Over Metsera Merger: A High-Stakes Court Drama Pfizer has initiated legal proceedings against Metsera and Novo Nordisk, alleging that Metsera breached their merger agreement. Pfizer's lawsuit seeks to block Metsera from terminating the agreement in favor of a higher offer from Novo Nordisk, arguing it threatens competition within the obesity drug market.This legal confrontation arises as Pfizer secures early antitrust …
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk
Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer’s bid, which w…
Pfizer is on its way to buying a biotech company before Novo Nordisk made a higher offer on Thursday.
BT
Ekstra BladetPfizer is on its way to buying a biotech company before Novo Nordisk made a higher offer on Thursday.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
